SCYNEXIS, Inc. Operating Lease Liability
SCYNEXIS, Inc. (SCYX) had Operating Lease Liability of $2.17 million as of 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-03-04
- 2025-12-31: Operating Lease, Liability $2.17M.
- 2024-12-31: Operating Lease, Liability $2.58M.
- 2024-09-30: Operating Lease, Liability $2.67M.
- 2024-06-30: Operating Lease, Liability $2.76M.
| Period end | Operating Lease, Liability |
|---|---|
| 2025-12-31 | $2.17M 10-K · filed 2026-03-04 |
| 2024-12-31 | $2.58M 10-K · filed 2025-03-12 |
| 2024-09-30 | $2.67M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $2.76M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $2.84M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $2.92M 10-K · filed 2024-03-28 |
| 2023-09-30 | $3.00M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $3.07M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $3.14M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $3.20M 10-K · filed 2023-03-31 |
| 2022-09-30 | $3.27M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $3.27M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $3.21M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $3.27M 10-K · filed 2022-03-29 |
| 2021-09-30 | $3.33M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $3.33M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $3.27M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $3.33M 10-K · filed 2021-03-29 |
| 2020-09-30 | $3.38M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $3.37M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $3.31M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $3.36M 10-K · filed 2020-03-11 |
| 2019-09-30 | $3.41M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $3.40M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $3.32M 10-Q · filed 2019-05-08 |
| 2019-01-01 | $3.37M 10-K · filed 2020-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |